$1.54 Billion is the total value of Avoro Capital Advisors LLC's 52 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | Buy | IMMUNOMEDICS INC | $259,602,000 | +26.0% | 16,064,461 | +9.0% | 16.83% | +5.3% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $106,070,000 | +90.6% | 1,189,524 | +98.9% | 6.88% | +59.3% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $104,516,000 | +7.7% | 7,263,122 | +12.8% | 6.77% | -10.0% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $80,265,000 | +84.9% | 4,398,101 | +18.5% | 5.20% | +54.5% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $74,996,000 | +15.8% | 1,102,884 | +40.4% | 4.86% | -3.2% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $72,479,000 | +107.6% | 1,841,896 | +63.8% | 4.70% | +73.5% |
| ARRY | Buy | ARRAY BIOPHARMA INC | $69,991,000 | +6.3% | 5,468,029 | +2.1% | 4.54% | -11.2% |
| ASND | Buy | ASCENDIS PHARMAsponsored adr | $67,342,000 | +13.5% | 1,681,024 | +2.7% | 4.36% | -5.1% |
| AVXS | Buy | AVEXIS INC | $65,983,000 | +56.2% | 596,217 | +36.5% | 4.28% | +30.6% |
| HZNP | Buy | HORIZON PHARMA PLC | $64,768,000 | +45.3% | 4,436,183 | +26.2% | 4.20% | +21.4% |
| ARGX | Buy | ARGENX SEsponsored adr | $50,820,000 | +423.2% | 804,875 | +87.4% | 3.29% | +337.5% |
| ZGNX | Buy | ZOGENIX INC | $50,596,000 | +40.6% | 1,263,313 | +23.1% | 3.28% | +17.5% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $48,351,000 | +52.6% | 1,068,534 | +17.8% | 3.13% | +27.6% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $42,028,000 | +29.1% | 5,253,450 | +25.0% | 2.72% | +7.9% |
| BMY | New | BRISTOL MYERS SQUIBB CO | $27,957,000 | – | 456,223 | +100.0% | 1.81% | – |
| TGTX | New | TG THERAPEUTICS INC | $27,015,000 | – | 3,294,463 | +100.0% | 1.75% | – |
| AZN | New | ASTRAZENECA PLCsponsored adr | $26,035,000 | – | 750,300 | +100.0% | 1.69% | – |
| VNDA | Buy | VANDA PHARMACEUTICALS INC | $21,416,000 | +21.1% | 1,408,946 | +42.6% | 1.39% | +1.2% |
| TLGT | Buy | TELIGENT INC | $18,329,000 | -40.3% | 5,049,431 | +10.3% | 1.19% | -50.1% |
| CASC | Buy | CASCADIAN THERAPEUTICS INC | $9,196,000 | +23.5% | 2,485,272 | +36.5% | 0.60% | +3.1% |
| APLS | New | APELLIS PHARMACEUTICALS INC | $7,316,000 | – | 396,635 | +100.0% | 0.47% | – |
| BDSI | New | BIODELIVERY SCIENCE INTL | $7,285,000 | – | 2,469,488 | +100.0% | 0.47% | – |
| NLNK | New | NEWLINK GENETICS CORP | $6,451,000 | – | 795,412 | +100.0% | 0.42% | – |
| VRAY | New | VIEWRAY INC | $5,824,000 | – | 730,161 | +100.0% | 0.38% | – |
| CBIO | New | CATALYST BIOSCIENCES INC | $5,456,000 | – | 400,000 | +100.0% | 0.35% | – |
| INCY | New | INCYTE CORP | $4,736,000 | – | 50,000 | +100.0% | 0.31% | – |
| FENC | Buy | FENNEC PHARMACEUTICALS INC | $2,726,000 | +272.9% | 206,000 | +209.0% | 0.18% | +210.5% |
| CLVS | New | CLOVIS ONCOLOGY INCcall | $264,000 | – | 675,000 | +100.0% | 0.02% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INCcall | $135,000 | – | 300,000 | +100.0% | 0.01% | – |
| MGNX | New | MACROGENICS INCcall | $37,000 | – | 14,500 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.